CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial

September 3, 2014 CEL-SCI Corporation today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) during August 2014. This brings the total study enrollment to 252 patients. “Given that summer months generally have a slower …

CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka

15th nation to join world’s largest Head and Neck cancer Phase III trial July 17, 2014 CEL-SCI Corporation today announced that Sri Lanka’s Ministry of Health has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Sri Lanka. This follows similar clearance to conduct the …

CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI’S Phase III Head and Neck Cancer Trial into Austria

July 8, 2014 CEL-SCI Corporation today announced that it has received regulatory clearance from the Austrian Federal Office for Safety in Health Care to begin patient enrollment in the Company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Austria is the 14th country to participate in CEL-SCI’s trial which is already active in numerous …